Federal Court of Appeal Canada v GlaxoSmithKline Inc
transfer pricing competitive external market
nadon j.a. subsequently listed following circumstances of considered reasonable in case @ bar:
consequently, in circumstances, possibility open appellant have been enter generic market cost of entry market have been high, considering both apotex , novopharm placed , positioned. without license agreement, appellant not have had access portfolio of other patented , trademarked products had access under license agreement.
the appeal allowed costs, setting aside tax court’s decision, , matter returned trial judge rehearing , reconsideration of matter in light of fca s reasons.
an appeal crown on reversal, , cross-appeal gsk respect case being returned tcc rehearing, subsequently made supreme court of canada, heard case on 13 january 2012.
Comments
Post a Comment